UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

Pharmaceutical research, 2005-01, Vol.22 (1), p.11-23

2005

Link zum Volltext

Verfügbarkeit prüfen

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

Advanced drug delivery reviews, 2008-03, Vol.60 (6), p.717-733

2008

Link zum Volltext

Verfügbarkeit prüfen

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

Clinical and translational science, 2024-03, Vol.17 (3), p.e13769-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000453

2020

Link zum Volltext

Verfügbarkeit prüfen

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

CPT: pharmacometrics and systems pharmacology, 2023-01, Vol.12 (1), p.95-109

2023

Link zum Volltext

Verfügbarkeit prüfen

Bicycle Robot Balance Control Based on a Robust Intelligent Controller

IEEE access, 2020, Vol.8, p.84837-84849

2020

Link zum Volltext

Verfügbarkeit prüfen

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab

CPT: pharmacometrics and systems pharmacology, 2018-01, Vol.7 (1), p.5-15

2018

Link zum Volltext

Verfügbarkeit prüfen

Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918

Drug metabolism and disposition, 2003-11, Vol.31 (11), p.1292

2003

Link zum Volltext

Verfügbarkeit prüfen

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety

Toxicology and applied pharmacology, 2014-09, Vol.279 (2), p.230-239

2014

Link zum Volltext

Verfügbarkeit prüfen

Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein

Clinical pharmacology and therapeutics, 2002-11, Vol.72 (5), p.474-489

2002

Link zum Volltext

Verfügbarkeit prüfen

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (6), p.1020

2017

Link zum Volltext

Verfügbarkeit prüfen

Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay

The Journal of pharmacology and experimental therapeutics, 2004-03, Vol.308 (3), p.1040

2004

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study

Modern rheumatology, 2015-01, Vol.25 (1), p.21-30

2015

Link zum Volltext

Verfügbarkeit prüfen

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Molecular carcinogenesis, 1995-07, Vol.13 (3), p.129-134

1995

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clinical cancer research, 2013-06, Vol.19 (11), p.3078-3087

2013

Link zum Volltext

Verfügbarkeit prüfen

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine

Clinical pharmacology and therapeutics, 1995-11, Vol.58 (5), p.492-497

1995

Link zum Volltext

Verfügbarkeit prüfen

Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

Journal of controlled release, 1996-05, Vol.39 (2), p.139-143

1996

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer

Clinical pharmacology in drug development, 2013-07, Vol.2 (3), p.205-212

2013

Link zum Volltext

Verfügbarkeit prüfen

Fairness and QoS Guarantees of WiMAX OFDMA Scheduling with Fuzzy Controls

EURASIP journal on wireless communications and networking, 2009-01, Vol.2009 (1), p.512507-512507

2009

Link zum Volltext

Verfügbarkeit prüfen

Fairness and QoS Guarantees of WiMAX OFDMA Scheduling with Fuzzy Controls

EURASIP journal on wireless communications and networking, 2009-01, Vol.2009 (1), Article 512507

2009

Link zum Volltext

Verfügbarkeit prüfen

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

Cancer chemotherapy and pharmacology, 2009-02, Vol.63 (3), p.417-425

2009

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity of panitumumab in combination chemotherapy clinical trials

BMC clinical pharmacology, 2011-11, Vol.11 (1), p.17-17, Article 17

2011

Link zum Volltext

Verfügbarkeit prüfen

Hydrolysis Kinetics of Diacetyl Nadolol

Journal of pharmaceutical sciences, 1987-12, Vol.76 (12), p.914-917

1987

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB-75: Concomitant use of panitumumab (Pmab) had no clinically significant effect on irinotecan (Iri) pharmacokinetics (PK)

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.LB-75-LB-75

2010

Link zum Volltext

Verfügbarkeit prüfen

Thermodynamic Properties of Fe-C-N and Fe-C-B-N Melts

Journal of iron and steel research, international, 2007, Vol.14 (1), p.21-24

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 394

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(350)
Mit Volltextzugriff
(370)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(293)
Life Sciences & Biomedicine
(166)
Humans
(103)
Technology
(95)
Physical Sciences
(74)
Male
(69)
Female
(58)
Materials Science
(49)
Middle Aged
(48)
Adult
(43)
Materials Science, Multidisciplinary
(41)
Science & Technology - Other Topics
(41)
Chemistry
(38)
Engineering
(38)
Animals
(36)
Biological And Medical Sciences
(36)
Medical Sciences
(34)
Aged
(33)
Physics
(33)
General & Internal Medicine
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

Bicycle Robot Balance Control Based on a Robust Intelligent Controller

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab

Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918

Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: Relevance for human safety

Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein

A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis

Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay

Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Differentiation of absorption and first-pass gut and hepatic metabolism in humans: Studies with cyclosporine

Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery

Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer

Fairness and QoS Guarantees of WiMAX OFDMA Scheduling with Fuzzy Controls

Fairness and QoS Guarantees of WiMAX OFDMA Scheduling with Fuzzy Controls

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

Immunogenicity of panitumumab in combination chemotherapy clinical trials

Hydrolysis Kinetics of Diacetyl Nadolol

Abstract LB-75: Concomitant use of panitumumab (Pmab) had no clinically significant effect on irinotecan (Iri) pharmacokinetics (PK)

Thermodynamic Properties of Fe-C-N and Fe-C-B-N Melts

Suchergebnisse filtern